Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 financing cash flow of $314K (cash outflow) rose 96.3% year over year, behind the +9371.4% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +212.3% a year.
Context
- Financing cash flow amounted to 204.4% of revenue in FY2025, up 202.7 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +96.3% toward the trailing-twelve-month pace of +9371.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 24.82M USD
- Year-over-year change
- +20780.0%
- 4-year CAGR
- -37.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.82M | +20780.0% |
| FY2024 | 2024-12-31 | (120K) | -100.1% |
| FY2023 | 2023-12-31 | 136.4M | +16635.6% |
| FY2022 | 2022-12-31 | 815K | -99.5% |
| FY2021 | 2021-12-31 | 164.9M | — |
Financing Cash Flow vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9371.4% is the highest of 11, against a peer median of +54.6%.
- Financing cash flow amounts to 147.5% of revenue for PRLD, versus a peer median of 233.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €232M EUR | +59.4% | +84.0% | 5175.1% | |
| LTM Mar 2026 | $212.95M USD | +1074.3% | +2184.5% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $122.33M USD | +380.3% | +92.7% | — |
| LTM Mar 2026 | $94.16M USD | +226.3% | -5.1% | 287.7% | |
| LTM Mar 2026 | $57.73M USD | +12.7% | +11.7% | 25658.2% | |
| LTM Mar 2026 | $50.66M USD | -51.5% | -16.6% | 179.5% | |
| LTM Mar 2026 | $42.1M USD | +263.6% | — | 60.8% | |
| LTM Mar 2026 | $24.66M USD | +9371.4% | +212.3% | 147.5% | |
| LTM Mar 2026 | $15.99M USD | -76.2% | — | 27094.9% | |
| LTM Mar 2026 | $7.05M USD | +49.8% | +31.2% | 62.9% | |
| LTM Mar 2026 | $569K USD | -68.7% | +48.1% | 4.1% | |
| Peer median (excluding PRLD) | — | +54.6% | +39.6% | 233.6% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.34M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.93M | 25.14M | 25.62M | 21.35M | 11.91M |
| Change in Working Capital | 3.63M | 932K | (10.48M) | 4.22M | 28.41M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.9M | (347K) | (2.27M) | 3.31M | (3.92M) |
| Other Working Capital | (278K) | 1.28M | (8.21M) | 911K | 32.33M |
| Other Non-Cash Items | 2.69M | 4.31M | (1.54M) | (3.05M) | 1.53M |
| Operating Cash Flow | (83.53M) | (83.73M) | (107.06M) | (102.89M) | (56.3M) |
| Capital Expenditures | (2.32M) | (3.02M) | (3.51M) | (764K) | (67K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (261.48M) | (119.22M) | (221.63M) | (52.69M) | (100.87M) |
| Sales of Investments | 0 | 203.93M | 190.5M | 143.65M | 154.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (263.8M) | 81.69M | (34.65M) | 90.19M | 53.46M |
| Debt Repayment | 0 | 0 | 0 | (395K) | (208K) |
| Common Stock Issued | 161.42M | 815K | 135.73M | 329K | 25.04M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.47M | 0 | 664K | (54K) | (17K) |
| Financing Cash Flow | 164.9M | 815K | 136.4M | (120K) | 24.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (182.44M) | (1.22M) | (5.31M) | (12.82M) | 21.97M |
| Free Cash Flow | (85.85M) | (86.75M) | (110.58M) | (103.65M) | (56.37M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.